

**Maricopa Integrated Health Systems
Formulary Prior Auth Criteria**

Drug: ProAmatine (Midodrine)

Therapy:

Is indicated for the treatment of symptomatic orthostatic hypotension (OH) that has been unaffected by standard clinical care

Inclusion

Request received with a lying, sitting and standing blood pressure
Failure of standard clinical cares

Black Box Warning:

Because ProAmatine can cause marked elevation of supine blood pressure, it should be used in patients whose lives are considerably impaired despite standard clinical care.

Additional information:

Monitor supine and standing blood pressure regularly. If excessive supine blood pressure exists, discontinue ProAmatine

Caution is recommended in renal or in the hepatic impaired population

Risk Factors/Contraindications:

Is contraindicated in patients with severe organic heart disease, acute renal disease, urinary retention, pheochromocytoma, or thyrotoxicosis. Also, if there is evidence of persistent or excessive supine hypertension, ProAmatine should not be used.

Precautions:

Risk for supine and sitting hypertension should be evaluated prior to therapy.

Blood pressure should be monitored regularly when taking concomitant vasoconstrictors

Patients with renal or hepatic impairment warrants caution

Patients should be advised to avoid cough and cold products as well as diet aids

Caution with a diabetic patient who is taking fludrocortisone, particularly if they have vision problem- may increase intraocular pressure

Authorizations:

Three months initially. Further authorization of six months with documented efficacy and a supine, sitting and standing blood pressure

Medical Director _____

Date _____